Lynx Investment Advisory’s Genmab GMAB Stock Holding History

Lynx Investment Advisory’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-21	Closed	-$528	–	370
2024 Q2	$528	Buy	+21	New	+$595	﹤0.01%	741

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lynx Investment Advisory's GMAB Position: Q3 2024 in Review

Lynx Investment Advisory sold out of Genmab (GMAB) in Q3 2024, closing a stake of 21 shares — an estimated $528 sold.

Lynx Investment Advisory first reported a position in GMAB in Q2 2024 and held it in 1 quarter. The position peaked at $528 in Q2 2024. 223 funds tracked by Wall St. Rank hold GMAB as of Q3 2024.

Lynx Investment Advisory reported no remaining Genmab position as of Q3 2024 after selling out during the quarter.
Lynx Investment Advisory sold 21 Genmab shares in Q3 2024, an estimated $528.
Lynx Investment Advisory first reported a position in Genmab in Q2 2024 and held it in 1 quarter.
Lynx Investment Advisory's Genmab position peaked at $528 in Q2 2024.
223 funds tracked by Wall St. Rank held Genmab as of Q3 2024.

Based on Lynx Investment Advisory's 13F filing for Q3 2024, filed 4 Nov 2024.